5 results about "Lapatinib" patented technology

The application discloses application of lapatinib in preparation of a rabies virus resisting medicine, and first discovers the rabies virus resisting activity of lapatinib, breaks the limitation of lapatinib only being used for treating tumors, and first proves the role of lapatinib in inhibiting rabies virus replication through in-vivo and in-vitro experiments, develops the potential application value of lapatinib in early treatment after rabies virus exposure, and provides a new use of lapatinib, i.e., using lapatinib as a candidate medicine for rabies treatment, especially specific treatment in the early stage of rabies virus infection, and fills the blank of specific treatment medicines after rabies virus exposure.

The invention relates to the field of biological medicine, in particular to application of a substance specifically combined with STAMBP to preparation of a tumor treatment drug or a tumor treatment drug enhancer. When the STAMBP gene inhibitor is a nucleic acid molecule, the nucleic acid molecule comprises a nucleic acid fragment for coding shRNA (short hairpin Ribonucleic Acid) for knocking down the STAMBP gene; and / or when the STAMBP gene inhibitor is a chemical small molecule substance, the STAMBP gene inhibitor is selected from one or more of the chemical small molecule substances selected from irinotecan hydrochloride, lapatinib disaccharide, emtricitinib, ranolazine or atavalopag. According to the present invention, the STAMBP knockout weakens the aerobic glycolysis in the PC cells, the accompanying PDK1 overexpression reduces the reduction of the capacity and the glycolysis rate, and the irinotecan hydrochloride and the lapatinib disaccharide for the STAMBP significantly enhance the chemosensitivity of the PC cells.

The invention discloses an application of lapatinib in preparation of an anti-rabies virus drug, the anti-rabies virus activity of lapatinib is found for the first time, the limitation that lapatinib is only used for treating tumors is broken through, and the effect of lapatinib in inhibition of rabies virus replication is proved for the first time through in-vivo and in-vitro experiments. The invention develops a potential application value of lapatinib in early treatment after rabies virus exposure, and provides a new application of lapatinib: the lapatinib is applied to a candidate drug for treating rabies, especially specific treatment for early stage of rabies virus infection, and fills the blank of no specific treatment drug after rabies virus exposure.

This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.

The application provides doxorubicin and lapatinib in constructing a zebrafish cardiotoxicity damage model and a drug screening method, and belongs to the technical field of biological medicine and animal model construction. The application discloses that doxorubicin and lapatinib can be used in combination to construct a doxorubicin-related zebrafish cardiotoxicity damage model for the first time, and provides a method for establishing a zebrafish cardiotoxicity damage model. The heart index of the application is very comprehensive, and the zebrafish cardiotoxicity damage model constructed by the application can be used to screen drugs of various different action mechanisms which have an improving effect on heart damage.